Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in de novo renal transplant
NCT00170885Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2005
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus in kidney transplant rejection (2 arms), sponsored by Novartis. Primary endpoint: Glomerular Filtration Rate at 6 months. Started May 2005; status: completed.
02
Drugs
everolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00170885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00170885.